Tobam Has $1.15 Million Stock Holdings in Natera, Inc. $NTRA

Tobam boosted its position in Natera, Inc. (NASDAQ:NTRA) by 24,935.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,007 shares of the medical research company’s stock after acquiring an additional 4,987 shares during the period. Tobam’s holdings in Natera were worth $1,147,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Groupama Asset Managment lifted its position in Natera by 19.5% during the 4th quarter. Groupama Asset Managment now owns 92,256 shares of the medical research company’s stock valued at $21,135,000 after purchasing an additional 15,072 shares during the period. MidFirst Bank bought a new stake in Natera in the fourth quarter valued at about $523,000. Kera Capital Partners Inc. lifted its stake in Natera by 21.7% in the fourth quarter. Kera Capital Partners Inc. now owns 1,659 shares of the medical research company’s stock valued at $383,000 after buying an additional 296 shares during the period. Kovitz Investment Group Partners LLC lifted its stake in Natera by 45.9% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 2,252 shares of the medical research company’s stock valued at $516,000 after buying an additional 709 shares during the period. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in Natera by 2,768,561.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 498,359 shares of the medical research company’s stock worth $114,170,000 after buying an additional 498,341 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Performance

NASDAQ:NTRA opened at $231.41 on Friday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $256.36. The stock has a market cap of $33.14 billion, a price-to-earnings ratio of -141.97 and a beta of 1.56. The stock has a 50-day moving average price of $208.20 and a two-hundred day moving average price of $215.52.

Insider Activity at Natera

In related news, Director Roelof Botha sold 78,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $220.31, for a total transaction of $17,184,180.00. Following the completion of the sale, the director directly owned 1,076,198 shares of the company’s stock, valued at approximately $237,097,181.38. This represents a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $218.43, for a total value of $655,290.00. Following the sale, the insider directly owned 137,643 shares of the company’s stock, valued at approximately $30,065,360.49. The trade was a 2.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 162,342 shares of company stock valued at $35,283,396 over the last 90 days. Insiders own 5.05% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. BTIG Research decreased their target price on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Morgan Stanley cut their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Wolfe Research assumed coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $256.53.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.